BRTX BioRestorative Therapies, Inc.

CIK 0001505497 50 ready 8-Ks latest September 10, 2026, 4:30 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (12)

Ready 8-Ks 50

Latest filing October 9, 2026, 4:05 PM ET

Top materiality 0.85

Event mix other_material ×32 · leadership ×6 · other ×5

Sentiment 5 pos · 8 neg · 37 neu

Latest earnings reported 2025-Q3

Executive change recent →

SHENANIGAN SCORE 3 / 7 see the board

Recent 8-K filings for BRTX

Highest-materiality recent filing

BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements

July 16, 2026, 5:30 PM ET leadership materiality 0.85 negative item 5.02 item 9.01

CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.
Board appointed director Katharyn Field as CEO, President, and interim CFO; she also serves as CEO of iSpecimen (ISPC).

Read filing →

September 10, 2026, 4:30 PM ET other material materiality 0.80 negative item 4.01 item 8.01 item 9.01

BioRestorative dismisses CBIZ, hires Bush CPA; audit committee probe ongoing

Dismissed CBIZ as auditor effective Aug 28, 2026; board approved Aug 26, audit committee ratified Sep 1.
September 2, 2026, 5:29 PM ET other material materiality 0.75 neutral item 3.03 item 5.03 item 7.01 item 9.01

BioRestorative Therapies announces 1-for-20 reverse stock split to regain Nasdaq compliance

1-for-20 reverse split effective 4:30 p.m. ET Sept 7, 2026; trading starts Sept 8, 2026 on Nasdaq under BRTX with new CUSIP 090655705.
September 1, 2026, 6:09 PM ET leadership materiality 0.75 negative item 4.01 item 5.02 item 9.01 ◈ executive_change ×5

BioRestorative appoints Mika Grasso interim CEO, Anna Skowron CFO; dismisses auditor CBIZ

Katharyn Field steps down as interim CEO/CFO, resigns from board; consulting deal with EEAK at $10k/month.
August 25, 2026, 5:00 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01

BioRestorative Therapies receives Nasdaq delisting notice for late 10-Q filing

Received Nasdaq delinquency notice on Aug 21, 2026 for failure to file Form 10-Q for Q2 2026.
August 14, 2026, 4:15 PM ET regulatory materiality 0.75 negative item 8.01 item 9.01

BioRestorative suspends ExoCR and BioX product shipments pending regulatory review

Suspended all orders and shipments of ExoCR and BioX biocosmeceutical product lines effective August 7, 2026.
July 16, 2026, 5:30 PM ET leadership materiality 0.85 negative item 5.02 item 9.01

BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements

CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.
June 12, 2026, 4:56 PM ET leadership materiality 0.75 neutral item 1.01 item 5.02 item 9.01 ◈ executive_change ×6◈ Material Agreements

BioRestorative Therapies enters $1M revolving loan at 12% with Bowery Group; board overhaul with 3 new directors

Entered $1,000,000 revolving loan agreement with Bowery Group LLC at 12% interest, 16% default rate, 1-year maturity.
May 29, 2026, 5:07 PM ET other material materiality 0.70 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes

BRTX shareholders approve 20x increase in authorized shares; CEO/CFO sign 3-year employment agreements

CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.
June 13, 2025, 7:59 PM ET other material materiality 0.78 positive item 7.01 item 9.01

BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects

Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
April 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired

Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.
November 13, 2024, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01 item 9.01

BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement

Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
May 24, 2024, 7:59 PM ET other material materiality 0.70 negative item 4.02

BioRestorative Therapies restates financials due to warrant classification error; no cash impact

Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
May 24, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting

Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.
February 8, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements

BioRestorative raises $8.1M via warrant exercise and new private placement warrants

Gross proceeds of $8.1M from exercise of existing warrants for 3,351,580 shares at $2.33/share.
February 5, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease

Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.
July 13, 2023, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×2

BRTX prices $2.1M registered direct offering of 685,033 shares at $3.03/share

Offering of 685,033 shares at $3.03/share for gross proceeds of approximately $2.1M; closing expected July 13, 2023.
September 13, 2022, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 4.01 item 5.03 item 7.01 item 9.01

BioRestorative exchanges preferred shares with Auctus, replaces auditor after Friedman/Marcum merger

Issued 1,543,158 Series B preferred shares to Auctus Fund in exchange for same number of Series A shares on Sept 8, 2022.
November 15, 2021, 6:59 PM ET other material materiality 0.60 positive item 3.02 item 7.01 item 9.01

BioRestorative closes $23M public offering, swaps $10M notes for equity

Closed underwritten public offering of 2.3M units at $10 each, gross proceeds ~$23M. Each unit: 1 common share + 1 warrant.
November 8, 2021, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×3

BioRestorative Therapies prices $23M public offering, uplists to Nasdaq; appoints CFO and new directors

Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.
October 20, 2021, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 9.01

BioRestorative Therapies enters agreements to exchange $9.25M notes and warrants for units in proposed offering

Exchanged aggregate $9,246,897 principal of convertible notes and warrants for units in proposed public offering.